DAC
TEVA icon

Dividend Assets Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Dividend Assets Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-291,711
Closed -$11.4M – 150
2013
Q2 		$11.4M Buy
+291,711
New +$11.4M 0.5% 46

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Dividend Assets Capital's TEVA Position: Q3 2013 in Review

Dividend Assets Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 291,711 shares — an estimated $11.4M sold.

Dividend Assets Capital first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $11.4M in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

  • Dividend Assets Capital reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Dividend Assets Capital sold 291,711 Teva Pharmaceuticals shares in Q3 2013, an estimated $11.4M.
  • Dividend Assets Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Dividend Assets Capital's Teva Pharmaceuticals position peaked at $11.4M in Q2 2013.
  • 705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Dividend Assets Capital's 13F filing for Q3 2013, filed 8 Nov 2013.